Science
Gordan Srkalovic: Can an Established Therapy Show Activity in FGFR2 – Mutated Cancers?
Gordan Srkalovic/uofmhealthsparrow.org

Gordan Srkalovic: Can an Established Therapy Show Activity in FGFR2 – Mutated Cancers?

Gordan Srkalovic, Medical Director of Sparrow Herbert-Herman Cancer Center, shared on LinkedIn:

“Very proud to share results of TAPUR trial using Sutent in patients with FGFR1/2 mutated cancers. Tried and true medication showed activity in the heavily pretreated patients with various solid tumors and FGFR2 mutations. I want to thank participating patients and express my gratitude to my co – authors.”

Title: Sunitinib in Patients With Various Solid Tumors With FGFR1/2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Authors: Gordan Srkalovic, Michael Rothe, Elizabeth Garrett-Mayer, Kathryn F. Mileham, Bamidele Adesunloye, Evan Pisick, Charles A. Leath III, Natalia Colocci, M. Dwight Chen, Funda Meric-Bernstam, Alissa S. Marr, Olatunji B. Alese, Steven Powell, Jens Rueter, Amin Benyounes, Corbin Pontious, Mark A. Lewis, Gary W. Thomas, Yelena Kier, Carmen J. Calfa, Margaret von Mehren, Jared D. Acoba, Dominique C. Hinshaw, Abigail Gregory, Gina N. Grantham, Susan Halabi, Richard L. Schilsky

Read the Full Article.

Gordan Srkalovic: Can an Established Therapy Show Activity in FGFR2 - Mutated Cancers?

Other articles featuring Gordan Srkalovic on OncoDaily.

Abigail Gregory Alissa S. Marr Amin Benyounes Bamidele Adesunloye cancer Carmen J. Calfa Charles A. Leath III Corbin Pontious Dominique C. Hinshaw Elizabeth Garrett-Mayer Evan Pisick FGFR2 mutations Funda Meric-Bernstam Gary W. Thomas Gina N. Grantham Gordan Srkalovic Jared D. Acoba Jens Rueter Kathryn F. Mileham M. Dwight Chen Margaret von Mehren Mark A. Lewis Michael Rothe Natalia Colocci Olatunji B. Alese OncoDaily Oncology Richard L. Schilsky Steven Powell Susan Halabi TAPUR trial Yelena Kier